In this context, an animal model of CKD with hyperparathyroidism and hyperphosphatemia showed that daily teriparatide improved bone mineralization and volume, suggesting retained anabolic activity despite elevated endogenous PTH [14,76]. This evidence concerns the gene PTH and chronic kidney disease.